Cannabinoids as New Drug Candidates for the Treatment of Glaucoma
| Autor: | Gia-Nam Nguyen, Erin Jordan, Alexander Piechot, Oliver Kayser |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Pharmacology
Cannabinoids Organic Chemistry Pharmaceutical Science Glaucoma Monoacylglycerol Lipases Analytical Chemistry Receptor Cannabinoid CB2 Receptor Cannabinoid CB1 Complementary and alternative medicine Drug Discovery Molecular Medicine lipids (amino acids peptides and proteins) Receptors Cannabinoid Endocannabinoids |
| Zdroj: | Planta Medica. 88:1267-1274 |
| ISSN: | 1439-0221 0032-0943 |
| DOI: | 10.1055/a-1665-3100 |
| Popis: | Glaucoma is a blinding eye disease that affects about 70 million patients globally today. The cannabinoid receptors and the endocannabinoid system have found attention for new drug concepts. This review will analyze the potential of cannabinoids, primarily tetrahydrocannabinol, THCVS, and cannabinol, as drug candidates and the role of CB1/CB2 receptors with regard to the pathophysiology of glaucoma. The mode of action of cannabinoids as innovative drug candidates and recent formulations for topical delivery will be discussed. Cannabinoid receptors with associated TRPV channels will be evaluated for their potential as drug targets. Especially the role of the endocannabinoid system (fatty acid amide hydrolase, monoacylglycerol lipase) impacting the prostaglandin network (cyclooxygenase, PGE, PGF) and neuroprotection by inhibition of nitric oxide radical formation is in the focus of this review. Delivery systems, including recent clinical trials, will be analyzed to evaluate the potential for innovative future ophthalmological drugs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|